首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2019年 10期HBV感染“新型”生物标志物的临床应用 => 其他 =>去甲肾上腺素或特利加..
去甲肾上腺素或特利加压素联合白蛋白治疗1型肝肾综合征效果及安全性比较的Meta分析
Efficacy and safety of norepinephrine combined with albumin versus terlipressin combined with albumin in treatment of type 1 hepatorenal syndrome: A Meta-analysis
文章发布日期:2019年09月05日  来源:  作者:覃艳新,龙富立,毛德文,等  点击次数:134次  下载次数:15次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】: 目的 对去甲肾上腺素、特利加压素联合白蛋白治疗1型肝肾综合征(HRS1)的效果及安全性进行系统评价。方法 通过检索PubMed、EMBASE、Medline、Cochrane Library、中国知网、万方和维普等国内外数据库有关去甲肾上腺素或特利加压素联合白蛋白治疗HRS1对比研究的文献。对文献进行质量评价。提取HRS逆转率、病死率、不良事件发生率、平均动脉压、肾功能等指标,应用Review Manager 5.3软件进行数据分析,各研究间的异质性采用χ2检验判断。二分类变量采用比值比 (OR) 分析,连续性变量采用加权均数差 (WMD)分析,两类变量均计算95%可信区间(95%CI)。结果 纳入符合标准的随机对照试验6篇,总样本量298例, 其中去甲肾上腺素联合白蛋白和特利加压素联合白蛋白组各149例。Meta分析显示两组的HRS逆转率(OR=0.95, 95%CI:0.60~1.49,P=0.81)、病死率(OR=0.84, 95%CI:0.51~1.41,P=0.51)、不良事件发生率(OR=0.42, 95%CI:0.16~1.07,P=0.07)、平均动脉压(SMD=0.05, 95%CI:-0.92~1.03,P=0.92)、肾功能等指标并无明显差异。结论 去甲肾上腺素联合白蛋白与特利加压素联合白蛋白治疗HRS1临床效果及安全性一致,临床上需要时可考虑使用去甲肾上腺素替代特利加压素。
【Abstract】: Objective To systematically review the efficacy and safety of norepinephrine combined with albumin versus terlipressin combined with albumin in the treatment of type 1 hepatorenal syndrome (HRS1). Methods PubMed, EMBASE, Medline, Cochrane Library, CNKI, Wanfang Data, and VIP were searched for comparative studies on norepinephrine combined with albumin versus terlipressin combined with albumin in the treatment of HRS1. Quality assessment was performed for articles. Related indicators were extracted, including hepatorenal syndrome (HRS) reversal rate, mortality rate, incidence of adverse events, mean arterial pressure, and renal function, and Review Manager 5.3 was used for data analysis. The chi-square test was used to determine the heterogeneity between studies. Odds ratio (OR) was used for the analysis of dichotomous variables, weighted mean difference (WMD) was used for the analysis of continuous variables, and 95% confidence interval (CI) was calculated for these two types of variables. Results A total of 6 randomized controlled trials which met the inclusion criteria were included, with a total sample size of 298 patients (149 patients in the norepinephrine+albumin group and 149 in the terlipressin+albumin group). The meta-analysis showed that there were no significant differences between the two groups in HRS reversal rate (OR=0.95, 95%CI: 0.6-1.49, P=0.81), mortality rate (OR=0.84, 95%CI: 0.51-1.41, P=0.51), incidence rate of adverse events (OR=0.42, 95%CI: 0.16-1.07, P=0.07), mean arterial pressure (standardized mean difference=0.05, 95%CI: -0.92 to 1.03, P=0.92), and renal function. Conclusion Norepinephrine combined with albumin has similar efficacy and safety as terlipressin combined with albumin in the treatment of HRS1, and terlipressin can be replaced by norepinephrine in clinical practice when necessary.
【关键字】:肝肾综合征; 去甲肾上腺素; 特利加压素; 血清白蛋白; Meta分析(主题)
【Key words】:hepatorenal syndrome; norepinephrine; terlipressin; serum albumin; Meta-analysis as topic
【引证本文】:QIN YX, LONG FL, MAO DW, et al. Efficacy and safety of norepinephrine combined with albumin versus terlipressin combined with albumin in treatment of type 1 hepatorenal syndrome: A Meta-analysis[J]. J Clin Hepatol, 2019, 35(10): 2266-2271. (in Chinese)
覃艳新, 龙富立, 毛德文, 等. 去甲肾上腺素或特利加压素联合白蛋白治疗1型肝肾综合征效果及安全性的比较Meta分析[J]. 临床肝胆病杂志, 2019, 35(10): 2266-2271.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号